MeiraGTx (MGTX) Projected to Post Earnings on Monday

Key Points

• MeiraGTx (MGTX) is set to announce its Q2 2025 earnings on August 11th, with analysts predicting an earnings per share of ($0.52) and revenue of $8.00 million.
• In its previous earnings release, MeiraGTx reported a loss of ($0.51) per share, significantly below the consensus estimate of ($0.38), and revenue of only $1.93 million compared to expectations of $4.44 million.
• Recent insider trading activity includes CEO Alexandria Forbes selling 47,500 shares for $378,575, resulting in a 3.37% reduction in their ownership, while CFO Richard Giroux sold 24,000 shares valued at $204,480.

MeiraGTx (NASDAQ:MGTX - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.52) per share and revenue of $8.00 million for the quarter.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.13). MeiraGTx had a negative return on equity of 241.05% and a negative net margin of 484.90%. The business had revenue of $1.93 million during the quarter, compared to the consensus estimate of $4.44 million. On average, analysts expect MeiraGTx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MeiraGTx Stock Up 3.4%

Shares of NASDAQ:MGTX traded up $0.26 during trading on Friday, hitting $7.88. 324,339 shares of the company's stock traded hands, compared to its average volume of 540,870. The company has a 50-day moving average price of $7.27 and a 200-day moving average price of $6.63. MeiraGTx has a 52 week low of $3.85 and a 52 week high of $8.98. The company has a current ratio of 1.53, a quick ratio of 1.51 and a debt-to-equity ratio of 2.34. The company has a market cap of $633.24 million, a price-to-earnings ratio of -3.40 and a beta of 1.25.

Wall Street Analyst Weigh In

MGTX has been the topic of a number of research analyst reports. Chardan Capital dropped their price objective on shares of MeiraGTx from $38.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen raised MeiraGTx from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th.

Insider Buying and Selling

In related news, CFO Richard Giroux sold 24,000 shares of the stock in a transaction that occurred on Tuesday, July 22nd. The stock was sold at an average price of $8.52, for a total transaction of $204,480.00. Following the completion of the transaction, the chief financial officer directly owned 853,494 shares of the company's stock, valued at approximately $7,271,768.88. This represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Alexandria Forbes sold 47,500 shares of the firm's stock in a transaction that occurred on Tuesday, July 8th. The shares were sold at an average price of $7.97, for a total value of $378,575.00. Following the completion of the transaction, the chief executive officer owned 1,361,483 shares of the company's stock, valued at approximately $10,851,019.51. This represents a 3.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.50% of the company's stock.

Hedge Funds Weigh In On MeiraGTx

A hedge fund recently bought a new stake in MeiraGTx stock. AQR Capital Management LLC acquired a new stake in MeiraGTx Holdings PLC (NASDAQ:MGTX - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 82,118 shares of the company's stock, valued at approximately $557,000. AQR Capital Management LLC owned about 0.10% of MeiraGTx at the end of the most recent reporting period. Institutional investors own 67.48% of the company's stock.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.